CAREERS

WE DISCOVER AND DEVELOP NOVEL,

DIFFERENTIATED THERAPIES IN CANCER AND BEYOND

ADDRESS UNMET MEDICAL NEEDS FOR PATIENTS IN CHINA AND GLOBALLY

Founded in 2016, we have established a robust in-house R&D engine underpinned by an oustanding discovery team and multi-dimensional discovery platform. We have strategically designed and developed a rich pipeline of 14 small molecule programs focused on oncology.

01---

Founders

-------------------------------------------------

Our exceptional discovery capability is driven by the experienced and visionary founds with a prolific track record of drug discovery, who have made contributions to over 50 discovery programs.

Dr. Yao-Chang Xu

Founder & CEO

Dr. Yao-Chang Xu

Founder & CEO

Dr. Yao-Chang Xu has more than 25 years of drug dis...

Dr. Hongping Yu

Senior VP and co-founder, Head of Chemistry

Dr. Hongping Yu

Senior VP and co-founder, Head of Chemistry

Dr. Hongping Yu has worked in drug discovery and de...

Dr. Zhui Chen

Senior VP and co-founder, Head of Biology

Dr. Zhui Chen

Senior VP and co-founder, Head of Biology

Dr. Zhui Chen is a seasoned biologist and drug hunt...

We address the large oncology market in China and globally.

Leveraging our robust in-house R&D capabilities, we have developed a rich pipeline of clinical and pre-clinical stage drug candidates

Our mission

-------------------------------------------------

The discovery, Development, And Clinical Verification

We are committed to focus on discovery of next-generation candidates with improved efficacy and safety and low risks， so that patients can benefit as soon as possible.

We strategically focus

small molecule precision oncology therapies & small molecule immuno-oncology therapies

Our Pipeline

Consists of a broad range of small-molecule
precision-oncology and immuno-oncology product candidates

Partnership

Excellent cooperation model and relationship

News & Press

bobapp下载地址_bob客户端下载_bob直播平台 Obtained Clinical Trial Approv...

12 July, 2020, Shanghai—bobapp下载地址_bob客户端下载_bob直播平台 Co., Ltd. (“Abbisko” hereafter) today announces that it ...

Abbisko and Sperogenix Announce An Exclusive Agreem...

Shanghai, Beijing, Hong Kong, July5th, 2021, bobapp下载地址_bob客户端下载_bob直播平台 Co., Ltd.(“Abbisko”) has entered in...

bobapp下载地址_bob客户端下载_bob直播平台 Announces Dosing of First Pati...

29 June, 2021, Shanghai – bobapp下载地址_bob客户端下载_bob直播平台 Co., Ltd. (“Abbisko” hereafter) today announced dosing...

bobapp下载地址_bob客户端下载_bob直播平台 Announces the Appointment of M...

4 June, 2021, Shanghai – bobapp下载地址_bob客户端下载_bob直播平台 Co., Ltd. (“Abbisko” hereafter) today announced the app...

bobapp下载地址_bob客户端下载_bob直播平台 Announces the Appointment of M...

4 June, 2021, Shanghai – bobapp下载地址_bob客户端下载_bob直播平台 Co., Ltd. (“Abbisko” hereafter) announced the appointme...

bobapp下载地址_bob客户端下载_bob直播平台 Obtained ABSK091 IND Approval ...

December 14, 2020, Shanghai—bobapp下载地址_bob客户端下载_bob直播平台 Co., Ltd. (“Abbisko” hereafter) today announces that...

OUR VISION

We aspire to become a leading biopharmaceutical company that discovers and develops novel, differentiated therapies in cancer and beyond, addressing critical unmet needs for patients in China and globally.

Investors

Since our establishment, we have completed five rounds of fund raising led by blue-chip investors. Our investor base is a testament to our capabilities and supports our future success with strong financial support and industry insights.